Zobrazeno 1 - 10
of 67
pro vyhledávání: '"BIA 10-2474"'
Autor:
A. Santos, Peter Pressman, Patrício Soares-da-Silva, José-Francisco Rocha, Helena Gama, Paul Moser, Amílcar Falcão, A. Wallace Hayes
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:391-403
This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIA 10-2474, a fatty acid amide hydrolase (FAAH) inhibitor, after first administration to healthy male and female participants. Participants (n = 116) were recru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35868e2bd8eb528d0e929e3dfdfb04a6
https://doi.org/10.1002/cpt.2290
https://doi.org/10.1002/cpt.2290
Publikováno v:
Critical Reviews in Toxicology. 51:65-75
In 2016, one subject died and four were hospitalized with neurological symptoms during a clinical trial with the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474. The present paper reviews the regulatory toxicology studies that were carried ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52be48cacd13341936820446e7b483d8
https://doi.org/10.1080/10408444.2020.1867821
https://doi.org/10.1080/10408444.2020.1867821
Autor:
Cátia Aires, Pedro Nuno Leal Palma, Patrício Soares-da-Silva, Nuno Pires, Ana I. Loureiro, Maria-Joao Bonifacio, Carlos Fernandes-Lopes, Paul Moser, Filipa Sousa
Publikováno v:
British Journal of Pharmacology
BACKGROUND AND PURPOSE In 2016, one person died and four others had mild-to-severe neurological symptoms during a phase I trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474. EXPERIMENTAL APPROACH Pharmacodynamic and pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5f00fa4d76cca04e584df2d71c11fd
https://doi.org/10.1111/bph.14973
https://doi.org/10.1111/bph.14973
Autor:
Christopher W. am Ende, Uthpala Seneviratne, Zhen Huang, Armand B. Cognetta, Douglas S. Johnson, Daisuke Ogasawara, Kimberly Lapham, Benjamin F. Cravatt, John Litchfield, Deane M. Nason
Publikováno v:
ACS Chemical Biology. 14:192-197
Clinical investigation of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10–2474 resulted in serious adverse neurological events. Structurally unrelated FAAH inhibitors tested in humans have not presented safety concerns, suggesting that BIA 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::705f6d4b62e85896baf9995e0c7e9e5a
https://doi.org/10.1021/acschembio.8b01097
https://doi.org/10.1021/acschembio.8b01097
Autor:
Maria João Bonifácio, Alexandre Beliaev, Humberto Ferreira, Carla Patricia da Costa Pereira Rosa, Patrício Soares-da-Silva, Nuno Pires, P. Nuno Palma, Ana I. Loureiro, Laszlo Erno Kiss
Publikováno v:
Chemmedchem
Fatty acid amide hydrolase (FAAH) can be targeted for the treatment of pain associated with various medical conditions. Herein we report the design and synthesis of a novel series of heterocyclic‐N‐carboxamide FAAH inhibitors that have a good ali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::281cc3b2186de22bf0e325dde139301b
http://europepmc.org/articles/PMC6582431
http://europepmc.org/articles/PMC6582431
Kniha
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Pharmaceutical Statistics. 16:100-106
Funding information: European Union's FP7 programme, Grant/Award Number: 602552 By setting the regulatory-approved protocol for a suite of first-in-human studies on BIA 10-2474 against the subsequent French investigations, we highlight six key design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59382b84e8d1ba95553b4c3b03170e08
https://doi.org/10.1002/pst.1801
https://doi.org/10.1002/pst.1801
Autor:
Shoshana J. Wodak, Vijay M. Shahani, Steven Molinski, Geoffrey Woollard, Cecilia G. Sanchez, Stephen S. MacKinnon, Naheed Kurji, Leonard D. Morayniss, Andreas Windemuth, Marcon Laforet
Publikováno v:
Biochemical and Biophysical Research Communications. 483:502-508
The investigational compound BIA 10-2474, designed as a long-acting and reversible inhibitor of fatty acid amide hydrolase for the treatment of neuropathic pain, led to the death of one participant and hospitalization of five others due to intracrani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10f4ff08ba08874a2a2a03b2ea234efd
https://doi.org/10.1016/j.bbrc.2016.12.115
https://doi.org/10.1016/j.bbrc.2016.12.115
Publikováno v:
Journal of pharmacological and toxicological methods. 102
The present paper describes the regulatory safety pharmacology studies that were carried out to support the clinical trial application for BIA 10–2474. Animal studies complied with worldwide regulatory guidelines (e.g. EEC Council Directive 75/318/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::007fec919dfee5bcdc2fdb9ca8be0993
https://pubmed.ncbi.nlm.nih.gov/31978535
https://pubmed.ncbi.nlm.nih.gov/31978535
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 111
In 2016 one person died and others had neurological sequelae during a clinical trial with BIA 10–2474 (3-(1-(cyclohexyl(methyl)carbamoyl)-lH-imidazol-4-yl)pyridine 1-oxide), a novel fatty acid amide hydrolase (FAAH) inhibitor being developed for th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763a6de3a0fa6c743b6481b191d0371a
https://pubmed.ncbi.nlm.nih.gov/31866344
https://pubmed.ncbi.nlm.nih.gov/31866344